Compare Quest Diagnostics Inc (DGX) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Williams Companies Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Williams Companies Inc trades at $73.07 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 3.5× Quest Diagnostics Inc's market cap, and Williams Companies Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Williams Companies Inc for 58 Days on average.
| DGX | WMB | |
|---|---|---|
Market Cap | $25.48B | $88.48B |
Volume | 941,866 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $247.45 | $79.40 |
52-Week Low | $173.49 | $56.51 |
Typical Hold Time | 56 Days | 58 Days |
Enterprise Value | $31.23B | $119.11B |
Dividend Yield | 1.49% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Williams Companies (WMB) trades at $72.68, up 1.71% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings beat expectations in Q1 2026, while Q2 narrowly missed. Technical indicators signal bullish momentum with support at $71-$72 and resistance at $73-$74. The company benefits from stable fee-based revenues and strategic positioning in natural gas infrastructure.
WMB presents a compelling investment case with strong cash flow generation, 79% analyst buy ratings, and $87.27 price target upside. Key risks include energy market volatility and high debt levels. The AI-driven data center growth provides tailwinds for natural gas demand, supporting long-term revenue stability. Investors should weigh the attractive dividend yield against exposure to commodity price fluctuations and capital expenditure requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
